March 22, 2018

Dr. Gene Barnett Receives Innovation Honor for Neuronavigation Advancements (Video)

Video profiles two key innovations and their impact

In the early 1980s, Cleveland Clinic neurosurgeon Gene Barnett, MD, MBA, had an “aha” moment when he saw an advertisement for a 3-D digitizer and envisioned how the technology could be used to map brain tumors. The ultimate result was his invention of the first of the frameless, freehand neuronavigation systems that have since become the standard used around the world for brain and spine surgery.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

That invention, together with Dr. Barnett’s instrumental role in developing laser interstitial thermal therapy (LITT) for brain tumors a decade ago, are the foundation for his newly announced selection as recipient of Cleveland Clinic’s 2017 Sones Innovation Award.

Dr. Barnett, who is Director of Cleveland Clinic’s Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, was presented the award March 21, 2018, by Cleveland Clinic CEO and President Tom Mihaljevic, MD. The annual honor recognizes achievements that reflect the spirit of pioneering Cleveland Clinic cardiologist F. Mason Sones, MD, to advance the Cleveland Clinic tradition of innovation to improve patient care.

This three-and-a-half-minute video profiles the neuronavigation advancements that earned Dr. Barnett this honor as well as the boundless commitment to patients that fuels his innovative spirit.

Advertisement

Related Articles

Cleveland Clinic physiatrist
March 22, 2024
The Vital Role of Oncology Rehabilitation (Podcast)

New program provides prehabilitation and rehabilitation services to help patients with cancer maintain and regain function

Doctors working on MGUS screening study
March 18, 2024
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

Ad